Emerging Research and Promising AML Treatment Approaches

December 21, 2018

  Register Now

As precision medicine allows doctors to be more and more attuned to a patient’s unique version of acute myeloid leukemia (AML), it’s critical to stay up-to-date with therapies targeted toward specific genetic mutations, because the standard of care may not provide the most benefit. What’s new in AML research?  How can your genetic profile influence treatment decisions? 

On Friday, December 21 at 3:00 PM Eastern (2:00 PM Central, 12:00 PM Pacific), leading experts will join Patient Power for a virtual 1-hour program to share recent breakthroughs in AML treatment and research announced at the 2018 American Society of Hematology (ASH) annual meeting. The panel will focus on new drug approvals, emerging clinical trial data and innovative, individualized approaches to treat distinct AML subtypes. How will these advances translate to the real world? Viewers will also learn how these developments will impact AML patients and other promising therapies in the pipeline.

Register now for this free online webinar to find out more about:

  • AML treatment news released at ASH 2018
  • How these novel agents will be used in real-world clinics
  • Genetic profiling and the role genetic markers play in AML disease course and treatment decisions
  • Important updates on AML clinical trial data
  • Where research is headed next

  Register Now
Host & Guests

Patient Advocate and Host


Assistant Professor, Department of Leukemia

Manager, Clinical Trial Support Center

AML Patient

Register Now

I understand that the information I've provided will only be accessed by Patient Power, LLC and its contracted third parties to mail (and email) helpful information about cancer and related products and services. Patient Power will not sell or transfer my name or contact information to any third party for their marketing use.

Log in    Already a member? Log in now.

Community Member Account

Help us to better understand you

Stay Informed

Can't read the security code? Refresh Code

If you are having issues with the registration form, please call (877) 668-2858 to register over the phone or email questions@patientpower.info.

This is a Patient Empowerment Network program produced by Patient Power in partnership with The Leukemia & Lymphoma Society. We thank Celgene Corporation, Daiichi Sankyo, Genentech, Helsinn and Novartis for their support.

Patient Empowerment Network
The Leukemia & Lymphoma Society (LLS)
Patient Power
tritt unserer Gemeinschaft bei Registrieren Sie sich für Veranstaltungen Lesen Sie unseren neuesten Blog

Page last updated on December 12, 2018